Study on the interaction between body weight and C1q tumour necrosis factor-related protein 1 in patients with myocardial infarction

doi:10.3969/j.issn.1674-8115.2022.06.013

Abstract

Abstract: Objective

·To investigate relationship between body weight and serum level of C1q tumor necrosis factor-related protein 1 (CTRP1), and its effect on the prognosis of patients with ST-segment elevation myocardial infarction (STEMI).

Methods

·A total of 200 patients diagnosed as STEMI in the Affiliated Huaian No.1 People's Hospital of Nanjing Medical University from January 2018 to January 2020 were selected. Their basic data, laboratory indexes and cardiac function indexes were collected and analyzed. After discharge, patients should continue to take oral drugs and have regular outpatient or telephone follow-up. According to whether serious adverse event (SAE) occurred or not within 1 year after discharge, patients were divided into SAE group and non-SAE group. Multivariate Logistic regression model was used to analyze the influencing factors of SAE in STEMI patients. The interaction between gender, age and body weight of patients and the serum level of CTRP1 was analyzed by forest plot.

Results

·A total of 192 patients were followed up. Among them, 24 patients (12.5%) developed SAE. Compared with the non-SAE group, patients in the SAE group were older [(67.08±10.30) years vs (62.99±9.04) years, P=0.043], had lower body weight [(65.41±9.45) kg vs (70.49±10.23) kg, P=0.023)], and had higher CTRP1 levels [(21.59±4.48) ng/mL vs (17.67±5.87) ng/mL, P=0.002)]. After adjusting for gender and age, multivariate Logistic regression analysis showed that high CTRP1 level was a risk factor for the incidence of SAE in STEMI patients (P=0.003), while body weight had no effect on the incidence of SAE (P>0.05). The results of subgroup analysis showed that there was an interaction between body weight and CTRP1 (P=0.011), and CTRP1 level was a risk factor for SAE occurring in patients with lower body weight (HR=22.303, P=0.003).

Conclusion

·There is an interaction between body weight and serum CTRP1 level in STEMI patients. The higher the level of serum CTRP1 in STEMI patients with lower body weight, the worse the prognosis they have.

Key words: C1q tumor necrosis factor-related protein 1 (CTRP1), ST-segment elevation myocardial infarction (STEMI), interaction, serious adverse event (SAE)

CLC Number:

R541.4

HU Xiao, ZHANG Xin, GU Yang. Study on the interaction between body weight and C1q tumour necrosis factor-related protein 1 in patients with myocardial infarction[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(6): 786-791.

Figures/Tables 3

TrendMD

References 25

1	HIRAKAWA Y, LAM T H, WELBORN T, et al. The impact of body mass index on the associations of lipids with the risk of coronary heart disease in the Asia Pacific region[J]. Prev Med Rep, 2015, 3: 79-82.
2	BALSAN G A, VIEIRA J L, OLIVEIRA A M, et al. Relationship between adiponectin, obesity and insulin resistance[J]. Rev Assoc Med Bras (1992), 2015, 61(1): 72-80.
3	JENSEN M D, RYAN D H, APOVIAN C M, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society[J]. Circulation, 2014, 129(25 Suppl 2): S102-S138.
4	中华医学会内分泌学分会肥胖学组. 中国成人肥胖症防治专家共识[J]. 中华内分泌代谢杂志, 2011, 27(9): 711-717.
	Obesity Group of Endocrinology Society of Chinese Medical Association. Expert consensus on prevention for Chinese adult obesity[J]. Chin J Endocrinol Metab, 2011, 27(9): 711-717.
5	BENJUMEA M V, ESTRADA A, CURCIO C L. Estimation equations for the height of Colombian elders using knee height[J]. Biomedica, 2019, 39(4): 639-646.
6	TANG J N, SHEN D L, LIU C L, et al. Plasma levels of C1q/TNF-related protein 1 and interleukin 6 in patients with acute coronary syndrome or stable angina pectoris[J]. Am J Med Sci, 2015, 349(2): 130-136.
7	JEON J H, KIM K Y, KIM J H, et al. A novel adipokine CTRP1 stimulates aldosterone production[J]. FASEB J, 2008, 22(5): 1502-1511.
8	ENGELI S, BÖHNKE J, GORZELNIAK K, et al. Weight loss and the renin-angiotensin-aldosterone system[J]. Hypertension, 2005, 45(3): 356-362.
9	中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南[J]. 中华心血管病杂志, 2015, 43(5): 380-393.
	Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. Guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction[J]. Chin J Cardiol, 2015,43(5):380-393.
10	国家体育总局. 2010年国民体质监测公报[EB/OL]. (2011-09-02) [2022-01-18]. https://www.sport.gov.cn/n4/n145/c328627/content_2.html.
	General Administration of Sports of China. 2010 National physical fitness monitoring bulletin[EB/OL]. (2011-09-02) [2022-01-18]. https://www.sport.gov.cn/n4/n145/c328627/content_2.html.
11	KERSBERGEN I, ROBINSON E. Blatant dehumanization of people with obesity[J]. Obesity (Silver Spring), 2019, 27(6): 1005-1012.
12	SONG X, TABÁK A G, ZETHELIUS B, et al. Obesity attenuates gender differences in cardiovascular mortality[J]. Cardiovasc Diabetol, 2014, 13: 144.
13	SHIGA T, KOHRO T, YAMASAKI H, et al. Body mass index and sudden cardiac death in Japanese patients after acute myocardial infarction: data from the JCAD study and HIJAMI-Ⅱ registry[J]. J Am Heart Assoc, 2018, 7(14): e008633.
14	王欢欢, 赵雪燕, 高展, 等. 体重指数对行介入治疗的急性ST段抬高型心肌梗死患者长期预后的影响[J]. 中国循环杂志, 2017, 32(4): 348-352.
	WANG H H, ZHAO X Y, GAO Z, et al. Impact of body mass index on long-term prognosis in patients of acute ST-segment elevation myocardial infarction after percutaneous coronary intervention[J]. Chin Circ J, 2017, 32(4): 348-352.
15	WANG Z J, ZHOU Y J, GALPER B Z, et al. Association of body mass index with mortality and cardiovascular events for patients with coronary artery disease: a systematic review and meta-analysis[J]. Heart, 2015, 101(20): 1631-1638.
16	KANEKO H, YAJIMA J, OIKAWA Y, et al. Obesity paradox in Japanese patients after percutaneous coronary intervention: an observation cohort study[J]. J Cardiol, 2013, 62(1): 18-24.
17	KANEMURA N, SHIBATA R, OHASHI K, et al. C1q/TNF-related protein 1 prevents neointimal formation after arterial injury[J]. Atherosclerosis, 2017, 257: 138-145.
18	SCHÄFFLER A, BUECHLER C. CTRP family: linking immunity to metabolism[J]. Trends Endocrinol Metab, 2012, 23(4): 194-204.
19	BARCHETTA I, CIMINI F A, CICCARELLI G, et al. Sick fat: the good and the bad of old and new circulating markers of adipose tissue inflammation[J]. J Endocrinol Invest, 2019, 42(11): 1257-1272.
20	DING Q X, WHITE S P, LING C, et al. Resistin and cardiovascular disease[J]. Trends Cardiovasc Med, 2011, 21(1): 20-27.
21	KIM K Y, KIM H Y, KIM J H, et al. Tumor necrosis factor-α and interleukin-1β increases CTRP1 expression in adipose tissue[J]. FEBS Lett, 2006, 580(16): 3953-3960.
22	孙恒, 齐潇雁, 肖新华. 肥胖对动脉粥样硬化的影响[J]. 中国动脉硬化杂志, 2019, 27(10): 829-834.
	SUN H, QI X Y, XIAO X H. The impact of obesity on atherosclerosis[J]. Chin J Arterioscler, 2019, 27(10): 829-834.
23	MUENDLEIN A, LEIHERER A, SAELY C, et al. The novel adipokine CTRP1 is significantly associated with the incidence of major adverse cardiovascular events[J]. Atherosclerosis, 2019, 286: 1-6.
24	KIM D, PARK S Y. C1q and TNF related protein 1 regulates expression of inflammatory genes in vascular smooth muscle cells[J]. Genes Genomics, 2019, 41(4): 397-406.
25	GU Y, HU X, GE P B, et al. CTRP1 aggravates cardiac dysfunction post myocardial infarction by modulating TLR4 in macrophages[J]. Front Immunol, 2021, 12: 635267.

Item	Non-SAE group （n=168）	SAE group （n=24）	t/χ² value	P value
Age/year	62.99±9.04	67.08±10.30	-2.037	0.043
Gender （male/female）/n	105/63	13/11	0.616	0.433
Body weight/kg	70.49±10.23	65.41±9.45	2.297	0.023
BMI/（kg·m^-2）	23.30±2.30	23.49±1.91	-0.373	0.709
Past medical history/n（%）
History of hypertension	93 （55.4）	16 （66.7）	1.094	0.295
History of diabetes mellitus	67 （39.9）	6 （25.0）	1.973	0.160
Family history of coronary heart disease	80 （47.6）	12 （50.0）	0.048	0.827
History of smoking	96 （57.1）	9 （37.5）	3.270	0.071
IRA （LAD/LCX/RCA）/n	69/45/54	10/7/7	0.104	0.949
Creatinine/（µmol·L^-1）	64.08±12.98	62.03±14.73	0.710	0.478
FBG/（mmol·L^-1）	6.35±1.34	6.21±1.13	0.472	0.637
LDL-C/（mmol·L^-1）	3.14±0.79	2.98±0.69	0.979	0.329
CTRP1/（ng·mL^-1）	17.67±5.87	21.59±4.48	-3.144	0.002
LVEF/%	49.40±9.89	50.75±8.65	-0.635	0.526

Item	Non-SAE group （n=168）	SAE group （n=24）	t/χ² value	P value
Age/year	62.99±9.04	67.08±10.30	-2.037	0.043
Gender （male/female）/n	105/63	13/11	0.616	0.433
Body weight/kg	70.49±10.23	65.41±9.45	2.297	0.023
BMI/（kg·m^-2）	23.30±2.30	23.49±1.91	-0.373	0.709
Past medical history/n（%）
History of hypertension	93 （55.4）	16 （66.7）	1.094	0.295
History of diabetes mellitus	67 （39.9）	6 （25.0）	1.973	0.160
Family history of coronary heart disease	80 （47.6）	12 （50.0）	0.048	0.827
History of smoking	96 （57.1）	9 （37.5）	3.270	0.071
IRA （LAD/LCX/RCA）/n	69/45/54	10/7/7	0.104	0.949
Creatinine/（µmol·L^-1）	64.08±12.98	62.03±14.73	0.710	0.478
FBG/（mmol·L^-1）	6.35±1.34	6.21±1.13	0.472	0.637
LDL-C/（mmol·L^-1）	3.14±0.79	2.98±0.69	0.979	0.329
CTRP1/（ng·mL^-1）	17.67±5.87	21.59±4.48	-3.144	0.002
LVEF/%	49.40±9.89	50.75±8.65	-0.635	0.526

Factor	β	S.E.	Wald	P value	OR	95%CI
Factor	β	S.E.	Wald	P value	OR	Lower limit	Upper limit
Gender
Male	‒	‒	‒	‒	Ref	‒	‒
Female	0.452	0.468	0.932	0.334	1.571	0.628	3.931
Age
≤63 years old	‒	‒	‒	‒	Ref	‒	‒
>63 years old	0.280	0.459	0.371	0.542	1.323	0.538	3.252
Body weight
≤70.75 kg	‒	‒	‒	‒	Ref	‒	‒
>70.75 kg	-0.951	0.491	3.756	0.053	0.386	0.148	1.011
CTRP1
≤17.95 ng·mL^-1	‒	‒	‒	‒	Ref	‒	‒
>17.95 ng·mL^-1	1.568	0.536	8.558	0.003	4.797	1.678	13.715
Constant	-2.881	0.618	21.699	0.000	0.056	‒	‒

Factor	β	S.E.	Wald	P value	OR	95%CI
Factor	β	S.E.	Wald	P value	OR	Lower limit	Upper limit
Gender
Male	‒	‒	‒	‒	Ref	‒	‒
Female	0.452	0.468	0.932	0.334	1.571	0.628	3.931
Age
≤63 years old	‒	‒	‒	‒	Ref	‒	‒
>63 years old	0.280	0.459	0.371	0.542	1.323	0.538	3.252
Body weight
≤70.75 kg	‒	‒	‒	‒	Ref	‒	‒
>70.75 kg	-0.951	0.491	3.756	0.053	0.386	0.148	1.011
CTRP1
≤17.95 ng·mL^-1	‒	‒	‒	‒	Ref	‒	‒
>17.95 ng·mL^-1	1.568	0.536	8.558	0.003	4.797	1.678	13.715
Constant	-2.881	0.618	21.699	0.000	0.056	‒	‒

[1]	Zhou Xinyu, Qiu Jianyin. Advances in empathy research from the perspective of the integration of neurobiology and computer science [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2026, 46(4): 545-554.
[2]	LI Wenli, JIN Lixing, ZHAO Yichao, ZHONG Fangyuan, SHI Yao, LEI Jie, PU Jun, GE Heng. Impact of left ventricular myocardial strain injury on secondary tricuspid regurgitation in acute STEMI assessed by cardiac magnetic resonance [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(12): 1578-1588.
[3]	HUANG Xinxin, LIU Chao, LÜ Qinyu, HU Guoqin, BAO Chenxi, ZHANG Yao, YI Zhenghui. Relationship between polymorphic interaction of glutamate pathway genes and anhedonia [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(5): 576-583.
[4]	LI Xiaochang, LI Mingyue, LEI Ming, WU Jian. Conservation of protein interaction between SAGE1 and INTS3 identified in 3 different types of primates [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(4): 444-453.
[5]	MOU Fan, HUANG Zhiwei, CHENG Yu, ZHAO Xue, LI Huafang, YU Shunying. Prediction of drug-drug interactions in clozapine combination therapy based on physiologically based pharmacokinetic model [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(11): 1414-1421.
[6]	JIANG Guixian, HU Ronggui, WU Hao. Screening of AAK1 interaction proteins and its role in regulating global translation level in cells [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(7): 821-828.
[7]	WU Yujing, GUO Qian, LIU Xiaohua, LI Guanjun. Progress in relationship between chronotype and technology addiction and its mechanism [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(4): 487-494.
[8]	Jiyu HAN, Yanhong WANG, Daqian WAN. Research progress and development trend of lower extremity exoskeleton rehabilitation robot [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2022, 42(2): 241-246.
[9]	Yi-kun MEI, Jing-cong TAN, An-jun WANG, Hui WANG, Ning-ning LIU. Advances in cell wall structure and Candida albicans-host interaction [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(9): 1246-1251.
[10]	Pei-kun HU, Jie HE, Lian-ming WU, Heng GE, Jian-rong XU, Jun PU. Effect of microvascular obstruction on left ventricle function and prognosis in patients with ST-segment elevation myocardial infarction [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(2): 173-179.
[11]	Ya-jie GAO, Wen-kun MA, Cheng-jie GAO, Yi ZHOU, Jing-wei PAN. Exploration of the predictive value of myocardial strain on ventricular remodeling after acute ST-segment elevation myocardial infarction [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(11): 1478-1484.
[12]	FENG Ze-hao1, ZHANG Qing1, CHAI Ye-zi1, SU Xuan1, SUN Bao-hang-xing1, LIU Qi-ming1, YAN Fu-hua2, JIANG Meng1#, PU Jun1#. Evaluation of effect of smoking on myocardial injury and prognosis in patients with acute ST-segment elevation myocardial infarction [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(5): 573-582.
[13]	LI Qian, GAO Jing-ze, LI Yun, SONG Kun, SHEN Qian-cheng. Bioinformatics analysis of esophageal squamous cell carcinoma genomic chip and prediction of targeted drug [J]. , 2020, 40(2): 194-.
[14]	MENG Guo-hao, HE Xin-heng, LU Shao-yong. Prediction of signalling pathway of synaptic cell adhesion molecules mediating early synapse formation based on bioinformatics [J]. , 2019, 39(12): 1366-.
[15]	TAO Jing, QIU Jian-yin, GU Hong-liang, et al. Impact of interaction between 5-HTT and ESR1 gene polymorphisms on depressive disorder in perimenopausal women [J]. , 2012, 32(6): 766-.